ClinicalTrials.gg
Not yet recruitingNCT06012162Updated Aug 25, 2023

Genomics in Heart Transplants

An observational study in Heart Transplantation, sponsored by Heinrich-Heine University, Duesseldorf. Not yet recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-25.

Sponsored by Heinrich-Heine University, Duesseldorf · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Myocardial Ischemia with a site in Germany — 5 open to participants now, 12 under way, none of them phase 3. Myocardial Ischemia · Germany.

Planned enrollment
13th of 18
200 · median 599
Started
2024
with 3 others
Observational
18 of 62
3 open now
Primary completion
2028-01
later than 10 of 11 live
Registered
58th of 62
by date

Among the 62 studies in Myocardial Ischemia with a site in Germany, this one is the 13th largest by planned enrollment of the 18 observational ones that give a count, is one of 4 that started in 2024, is one of 18 observational ones, reaches primary completion later than 10 of the 11 other live ones, and was the 58th registered.

Myocardial Ischemia

1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.

Browse Myocardial Ischemia studies →

Open to participants now

5 of the 62 studies in Myocardial Ischemia with a site in Germany are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Myocardial Ischemia with a site in Germany, or all of them as a file.
02

Study summary

A cross-sectional analysis of 200 heart transplant recipients, combining in-depth phenotyping and risk factor assessment (cardiac MRI, coronary angiogram with OCT, cardiorespiratory exercise tests, exogenic factors like nutrition, smoking, lipid profile) with short-read whole-genome sequencing to elucidate the interplay of established PRS from the literature and exogenic risk factors with respect to HTx outcomes will be carried out.

Besides that, a long-read whole-genome sequencing of 100 newly transplanted recipients and their corresponding donors and extend latest bioinformatics methods developed by the study to analyze long-read data will be performed. This will enable a comprehensive and integrated analysis of structural variants, polygenic risk, high-penetrance variant genotypes, immunogenetic (major and minor histocompatibility), and individual lifestyle risk factors in a unique donor-recipient cohort, elucidating the extent of within-cohort variability and cross-correlations between the considered potential risk factors and an exploratory analysis of the utility of genetic risk scores in light of the study results will be carried out.

Read the detailed description

Background: Heart transplantation (HTx) is the treatment of choice for patients with end-stage heart failure who remain symptomatic despite optimal medical therapy. Even with best-practice follow-up care, one out of eight HTx patients eventually die of ischemic cardiomyopathy and recurrent acute myocardial infarction (AMI). Classical risk factors like the recipient indication for heart transplantation explain a fraction of adverse outcomes, but no conventional risk factor alone satisfactorily predicts the probability of cardiac allograft vasculopathy (CAV) or recurrent AMI in HTx patients; in addition, the underlying pathomechanisms are poorly understood.

Therefore, there is an urgent need for an improved understanding of the factors contributing to recurrent myocardial ischemia in HTx patients. Recent large-scale studies of the genetic architecture of coronary artery disease in the general population indicate that polygenic risk scores (PRS) explain more disease risk than any single non-genetic risk factor, but, due to a lack of longitudinal follow-up studies with deep phenotyping, PRS have not yet been widely adopted in clinical practice. Furthermore, current genetic studies are based on microarrays or short-read sequencing, severely limiting their ability to characterize the effect of complex or structural genetic variation, in the whole human genome as well as in key loci of potential importance for HTx outcomes, affecting, e.g., lipid metabolism (e.g. LPA) and immunogenetic compatibility (e.g. the major histocompatibility complex).

In summary, there is presently no study leveraging the improved ability to resolve human genomes with long-read sequencing technologies in a deeply phenotyped cohort for an improved understanding of recurring myocardial ischemia.

Study design and aims: In an innovative three-component study design, comprehensive phenotyping with the latest long-read sequencing technology and algorithmic advances in computational genomics to elucidate the interplay of genetic and non-genetic risk factors of myocardial ischemia in HTx patients at unprecedented resolution and pave the way towards detailed risk stratification and tailored treatment, will be combined

Significance and translational potential: By enabling the integrated analysis of structural variants, high-penetrance complex variants, and high-resolution immunogenetics, long-read sequencing will enable improved genetic models of the development of ischemia in HTx patients and contribute to an improved understanding of underlying pathomechanisms. Based on this, the investigators will be able to propose schemes to incorporate integrated risk scores in future clinical trials for personalized treatment stratification.

03

Conditions studied

  • Heart Transplantation

Browse trials for

Keywords

  • heart transplantation
  • long-read genomics
  • risk stratification
  • myocardial ischemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing heart transplantation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients > 18 years old undergoing heart transplantation in our centre

Exclusion criteria

Exclusion Criteria:

  • \< 18 years
  • incapable of giving consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. rate of Clinically significant ischemia

    defined by cardiac allograft vasculopathy (CAV) grade \>1 \& cardiac magnetic resonance imaging (cMRI)

    Time frame: 5 years

Secondary outcomes

  1. cardiovascular death

    cardiovascular event as primary cause of death

    Time frame: 5 years

  2. myocardial infarction

    Incidence of Type I or II myocardial infarction (assessed by CMR, electrocardiogram, laboratory parameters according to the 4th universal definition of myocardial infarction)

    Time frame: 5 years

  3. Hospitalisation (w/o allograft rejection)

    All-cause hospitalisation with exception of acute allograft rejection

    Time frame: 5 years

  4. Cardiac allograft vasculopathy (macrocirculatory)

    Incidence: Coronary angiogram (+/- optic coherence tomography (OCT))

    Time frame: 5 years

  5. number of coronary microvascular dysfunction

    measured by fractional flow reserve

    Time frame: 5 years

  6. number of coronary microvascular dysfunction

    measured by cardiac magnetic resonance imaging

    Time frame: 5 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2024; primary completion for Jan 2028, 48 months later.

Of 165 non-industry observational studies under Myocardial Ischemia, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 127. This study's planned 48 months is close to that.

Counting every sponsor, half of 204 studies reached it within 40 months; a quarter within 21 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2023
First posted
Aug 25, 2023
StartEst.
Jan 2024
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
Aug 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06012162
Responsible party
Sponsor
First posted
Aug 25, 2023
Start date
Jan 2024 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Aug 25, 2023

Study contacts

Daniel Oehler, MD
Contact
Daniel.oehler@med.uni-duesseldorf.de
+492118118800
Lisa Dannenberg, MD
Contact
lisa.dannenberg@med.uni-duesseldorf.de
+49211811800
Malte Kelm, Prof.
study chair · Clinic for Cardiology, Pneumology and Angiology at University Hospital Düsseldorf

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion